0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]

NovoCure Limited - Ordinary Shares (NVCR)  More Company Research Source: Yahoo! Finance
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
NovoCure Limited Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan. Transitioned to a multi-indication platform company following the FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle. Stabilized the core glioblastoma (GBM) business in mature markets, shifting focus toward high-return potential indications like pancreatic cancer over slower-growing lung cancer segments. Restructured the leadership team by combining scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles. Leveraged an existing 'torso' sales force to launch Optune Pax, minimizing incremental commercial spend by utilizing established physician relationships in oncology. Addressed a temporary Medicare billing adm [Read more]
IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
NVCR alerts
from News Quantified
NVCR
NEWS
NVCR
Earnings
NVCR
Analyst Actions
NVCR
SEC Filings
Stockreport

NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]

NovoCure Limited - Ordinary Shares  (NVCR) 
More Company Research Source: Yahoo! Finance
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
NovoCure Limited Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan. Transitioned to a multi-indication platform company following the FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle. Stabilized the core glioblastoma (GBM) business in mature markets, shifting focus toward high-return potential indications like pancreatic cancer over slower-growing lung cancer segments. Restructured the leadership team by combining scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles. Leveraged an existing 'torso' sales force to launch Optune Pax, minimizing incremental commercial spend by utilizing established physician relationships in oncology. Addressed a temporary Medicare billing adm [Read more]
IMPACT SNAPSHOT
EVENT TIME:
NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS